arrow
H

Hong Zebger-Gong

Bayer AG
H指数:24
被引数:2,200

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma

一项多中心剂量定义/扩展性 Ib 期研究,评估regorafenib联合pembrolizumab作为一线疗法在晚期肝细胞癌患者中的疗效。

2025-11-010
PRE
Population Pharmacokinetic Analysis of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

达波替单抗德鲁克坦(Dato-DXd)的群体药代动力学分析,该药是一种TROP2靶向抗体药物偶联物,用于治疗晚期实体瘤患者。

2025-10-010
OAAI
A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLC

Datopotamab Deruxtecan在EGFR突变非小细胞肺癌患者中的合并分析

2025-06-120
OAAI
Efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously-treated EGFR-mutated advanced non-small cell lung cancer (NSCLC): A pooled analysis of TROPION-Lung01 and TROPION-Lung05

达波替安德鲁克坦(Dato-DXd)在既往治疗过的EGFR突变型晚期非小细胞肺癌(NSCLC)患者(pts)中的有效性与安全性:TROPION-Lung01和TROPION-Lung05的合并分析

2024-12-012
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023-11-0111
PRE
Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase III study TROPION-Lung01
2023-10-0128
PRE
Regorafenib plus nivolumab in patients with mismatch repair- proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

Regorafenib联合nivolumab治疗错配修复熟练/微卫星稳定的转移性结直肠癌患者: 一项单臂、开放标签、多中心2期研究

2023-04-0143
OA